Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04471675 | Evaluation of the Safety and Efficacy of Albumin-bound Docetaxel | unknown | Phase 1 | 208 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 31, 2022 | clinicaltrials |
| NCT04811118 | The Comparison of the Pharmacokinetics of Albumin-bound Docetaxel and Taxotere | unknown | Phase 1 | 27 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 31, 2022 | clinicaltrials |
| NCT05114915 | A Study to Evaluate the Safety and Efficacy of Docetaxel for Injection (Albumin-bound)in Different Dose Regimens in Patients With Advanced Solid Tumors | unknown | Phase 1 | 144 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 31, 2022 | clinicaltrials |
| NCT05136937 | A Clinical Study of Intratumoral Administration of RT-01 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 18 | Wuxi People's HospitalOTHER | 1 | Jan 31, 2022 | clinicaltrials |
| NCT05212896 | An Exploratory Clinical Study of BC006 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 90 | Dragonboat Biopharmaceutical Company LimitedINDUSTRY | 1 | Jan 28, 2022 | clinicaltrials |
| NCT05212987 | Study of FCN-098 in Patients With Advanced Solid Tumor | unknown | Phase 1 | 43 | Fochon Pharmaceuticals, Ltd.INDUSTRY | 1 | Jan 28, 2022 | clinicaltrials |
| NCT02675946 | CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | unknown | Phase 1 | 72 | Curegenix Inc.INDUSTRY | 2 | Jan 26, 2022 | clinicaltrials |
| NCT04679038 | A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 222 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05125523 | A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors | unknown | Phase 1 | 264 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 25, 2022 | clinicaltrials |
| NCT05122572 | RT-01 Monotherapy and in Combination With Nivolumab in Patients With Advanced Solid Tumors | unknown | Phase 1 | 36 | Wuxi People's HospitalOTHER | 1 | Jan 20, 2022 | clinicaltrials |
| NCT04122339 | MAX-10181 Given Orally to Patients With Advanced Solid Tumor | unknown | Phase 1 | 30 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Jan 19, 2022 | clinicaltrials |
| NCT04183764 | MAX-40279-01 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Jan 19, 2022 | clinicaltrials |
| NCT05196360 | MAX-10181 in Patients With Advanced Solid Tumor(PD-L1) | unknown | Phase 1 | 80 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Jan 19, 2022 | clinicaltrials |
| NCT05153096 | Evaluation of the Safety and Efficacy of NBL-015 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 410 | NovaRock Biotherapeutics, LtdINDUSTRY | 1 | Jan 3, 2022 | clinicaltrials |
| NCT05172856 | A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors | unknown | Phase 1 | 110 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Dec 29, 2021 | clinicaltrials |
| NCT04990739 | Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | MetaboMed IncOTHER | 2 | Dec 17, 2021 | clinicaltrials |
| NCT05154604 | A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours | unknown | Phase 1 | 156 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 0 | Dec 13, 2021 | clinicaltrials |
| NCT05149027 | A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combine With Toripalimab in Patients With Advanced HCC and Other Solid Tumors | unknown | Phase 1 | 67 | Harbour BioMed (Guangzhou) Co. Ltd.INDUSTRY | 0 | Dec 8, 2021 | clinicaltrials |
| NCT04941339 | A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors | unknown | Phase 1 | 74 | Shanghai Miracogen Inc.INDUSTRY | 1 | Dec 3, 2021 | clinicaltrials |
| NCT05046847 | A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant Tumors | unknown | Phase 1 | 30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 3, 2021 | clinicaltrials |
| NCT05049265 | Clinical Study of JS007 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 42 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT03710265 | SHR-1701 in Metastatic or Locally Advanced Solid Tumors | unknown | Phase 1 | 206 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT03662815 | Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor | unknown | Phase 1 | 30 | Sir Run Run Shaw HospitalOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT03869632 | First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors | unknown | Phase 1 | 36 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Nov 16, 2021 | clinicaltrials |
| NCT05119933 | A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation | unknown | Phase 1 / Phase 2 | 55 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT04719065 | A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Solid Tumor | unknown | Phase 1 | 90 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Nov 1, 2021 | clinicaltrials |
| NCT05009966 | Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor | unknown | Phase 1 | 272 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 25, 2021 | clinicaltrials |
| NCT05072522 | A Study of SKLB1028 in Patients With Advanced Solid Tumor | unknown | Phase 1 | 98 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 11, 2021 | clinicaltrials |
| NCT05060263 | A Study of of HOT1030 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 42 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Sep 29, 2021 | clinicaltrials |
| NCT05058352 | A Study of HS269 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 36 | Zhejiang Hisun Pharmaceutical Co. Ltd.INDUSTRY | 1 | Sep 27, 2021 | clinicaltrials |
| NCT04981691 | Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors(Amaretto) | unknown | Phase 1 | 12 | Ruijin HospitalOTHER | 1 | Sep 17, 2021 | clinicaltrials |
| NCT04859777 | A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors | unknown | Phase 1 | 70 | Monopteros Therapeutics Inc.INDUSTRY | 1 | Sep 16, 2021 | clinicaltrials |
| NCT04972422 | A Phase 1b Study of ZN-c3 in Chinese Subjects | unknown | Phase 1 | 38 | Zentera Therapeutics HK LimitedINDUSTRY | 1 | Sep 5, 2021 | clinicaltrials |
| NCT05028478 | A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies | unknown | Phase 1 / Phase 2 | 164 | Curon Biopharmaceutical (Australia) Co Pty LtdINDUSTRY | 0 | Aug 31, 2021 | clinicaltrials |
| NCT05020119 | Neoantigen-expanded Autologous Immune Cell Therapy | unknown | Phase 1 | 9 | Chang Gung Memorial HospitalOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT04526470 | Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer | unknown | Phase 1 / Phase 2 | 55 | Seoul National University Bundang HospitalOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT04687423 | Study of FCN-011 in Patients With Advanced Solid Tumor（Phase I）and NTRK Fusion Positive Advanced Solid Tumor （Phase II） | unknown | Phase 1 | 82 | Fochon Pharmaceuticals, Ltd.INDUSTRY | 1 | Aug 18, 2021 | clinicaltrials |
| NCT03374007 | Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma(GB226) | unknown | Phase 1 | 72 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT04802980 | A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor | unknown | Phase 1 | 72 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Jul 28, 2021 | clinicaltrials |
| NCT04871347 | The Safety and Efficacy of TWP-101 in Patients With Advanced Solid Tumor | unknown | Phase 1 | 58 | Shandong TheraWisdom Biopharma Co., Ltd.INDUSTRY | 1 | Jul 27, 2021 | clinicaltrials |
| NCT04237805 | A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients | unknown | Phase 1 / Phase 2 | 280 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Jul 8, 2021 | clinicaltrials |
| NCT04937842 | Microtransplantation for Advanced and Relapsed Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Jun 24, 2021 | clinicaltrials |
| NCT04906473 | Safety,Tolerability, Pharmacokinetic,Pharmacodynamics and Efficacy of KY100001 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 109 | Kunming Pharmaceuticals, Inc.INDUSTRY | 0 | May 28, 2021 | clinicaltrials |
| NCT04556669 | Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors | unknown | Phase 1 | 30 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | May 27, 2021 | clinicaltrials |
| NCT04890587 | A Phase I Study of AL8326 in Advanced Solid Tumor | unknown | Phase 1 | 40 | Advenchen Laboratories Nanjing Ltd.INDUSTRY | 1 | May 18, 2021 | clinicaltrials |
| NCT04891653 | A Phase I Study of BR790 in Subjects With Advanced Solid Tumors | unknown | Phase 1 | 48 | Jiangxi Qingfeng Pharmaceutical Co. Ltd.INDUSTRY | 0 | May 18, 2021 | clinicaltrials |
| NCT04337463 | ATG-008 Combined With Toripalimab in Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Sichuan UniversityOTHER | 1 | May 17, 2021 | clinicaltrials |
| NCT03552406 | Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 33 | ISU Abxis Co., Ltd.INDUSTRY | 1 | May 6, 2021 | clinicaltrials |
| NCT04873440 | An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma | unknown | Phase 1 / Phase 2 | 10 | Chinese PLA General HospitalOTHER | 1 | May 5, 2021 | clinicaltrials |
| NCT03852823 | Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours | unknown | Phase 1 | 192 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jan 31, 2022source: clinicaltrials